ImageneBio (NASDAQ:IMA) Posts Quarterly Earnings Results, Misses Estimates By $1.44 EPS

ImageneBio (NASDAQ:IMA) announced its quarterly earnings data on Wednesday. The company reported ($2.91) EPS for the quarter, missing analysts’ consensus estimates of ($1.47) by ($1.44), FiscalAI reports.

ImageneBio Stock Performance

Shares of ImageneBio stock traded up $0.09 on Thursday, reaching $8.70. 409 shares of the company’s stock were exchanged, compared to its average volume of 28,579. The firm’s 50-day moving average is $8.25 and its two-hundred day moving average is $12.75. ImageneBio has a 52 week low of $7.24 and a 52 week high of $23.28. The company has a market capitalization of $34.89 million, a P/E ratio of -1.13 and a beta of 0.42.

Institutional Trading of ImageneBio

Several large investors have recently modified their holdings of the business. XTX Topco Ltd grew its position in shares of ImageneBio by 350.6% in the 1st quarter. XTX Topco Ltd now owns 56,452 shares of the company’s stock worth $72,000 after buying an additional 43,924 shares during the last quarter. Goldman Sachs Group Inc. raised its holdings in ImageneBio by 62.4% in the first quarter. Goldman Sachs Group Inc. now owns 76,464 shares of the company’s stock worth $98,000 after purchasing an additional 29,369 shares in the last quarter. Aldebaran Capital LLC purchased a new position in ImageneBio during the third quarter valued at $159,000. BML Capital Management LLC purchased a new stake in shares of ImageneBio in the 3rd quarter worth about $1,487,000. Finally, Vanguard Group Inc. bought a new position in shares of ImageneBio in the 3rd quarter worth about $1,902,000. 75.00% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several equities analysts have recently weighed in on IMA shares. Weiss Ratings began coverage on ImageneBio in a report on Wednesday, October 22nd. They issued a “sell (e-)” rating for the company. Wedbush cut their price objective on ImageneBio from $25.00 to $23.00 and set a “neutral” rating for the company in a report on Friday, July 25th. Wall Street Zen upgraded shares of ImageneBio to a “hold” rating in a report on Friday, September 26th. Leerink Partners assumed coverage on shares of ImageneBio in a research report on Friday, October 24th. They issued an “outperform” rating and a $30.00 price objective for the company. Finally, Leerink Partnrs upgraded shares of ImageneBio to a “strong-buy” rating in a research note on Friday, October 24th. One research analyst has rated the stock with a Strong Buy rating, one has given a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average price target of $26.50.

ImageneBio Company Profile

ImageneBio, Inc, a clinical-stage biotechnology company, develops therapeutics for immunological and inflammatory diseases. Its lead product includes IMG-007, a non-depleting anti-OX40 mAb that has completed Phase 2a clinical trials for the treatment of atopic dermatitis and alopecia areata. The company was formerly known as Ikena Oncology, Inc and changed its name to ImageneBio, Inc in July 2025.